Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
NCT03274778 · Oncology Institute of Southern Switzerland · NA · withdrawn · last registry update 2025-11-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruitment difficulty due to eligibility criteria.” | – | Registry record, Oncology Institute of Southern Switzerland |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against JAK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Also stopped (withdrawn): Incepta Pharmaceuticals Ltd, Baricitinib + Placebo (NCT05056558)
- 2026-10-27Phase 3 first posted: AbbVie, Upadacitinib + Placebo for Upadacitinib (NCT07896434)
- 2026-10-16Results posted on the registry: Julie Nangia, Ruxolitinib + Placebo (for Ruxolitinib) (NCT02928978)
- 2026-10-15Results posted on the registry: Rohit Aggarwal, MD, Nintedanib + Placebo (NCT05799755)
- 2026-10-07Results posted on the registry: William Damsky, Abrocitinib 200 mg (NCT05650736)
- 2026-09-16Also stopped (terminated): Ryvu Therapeutics SA, RVU120 + Ruxolitinib (NCT06397313)
- 2026-09-16Phase 3 first posted: Pfizer, Abrocitinib + Placebo (NCT07823595)
- 2026-09-09Also stopped (withdrawn): Vanderbilt University Medical Center, Baricitinib 4 MG + Placebo (NCT05858515)
- 2026-08-19Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT07772492)
- 2026-08-13Results posted on the registry: AbbVie, ABT-494 (NCT02782663)
- 2026-08-11Results posted on the registry: Eli Lilly and Company, Baricitinib (NCT05074420)
- 2026-08-11Also stopped (terminated): Eli Lilly and Company, Baricitinib (NCT05074420)
- 2026-08-04Results posted on the registry: Syntara, PXS-5505 (NCT04676529)
- 2026-07-27Results posted on the registry: Alfasigma S.p.A., Filgotinib + Placebo to match filgotinib (NCT03025308)
- 2026-07-23Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Ruxolitinib (NCT07722611)
- 2026-07-16Results posted on the registry: Bristol-Myers Squibb, SAR302503 (NCT01523171)
- 2026-07-16Also stopped (terminated): Bristol-Myers Squibb, SAR302503 (NCT01523171)
- 2026-07-15Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Ruxolitinib (NCT05998408)
- 2026-07-15Also stopped (terminated): Alfasigma S.p.A., Filgotinib + Filgotinib (NCT06222034)
- 2026-07-10Results posted on the registry: Eli Lilly and Company, Baricitinib + TNF Inhibitor (NCT04086745)
- 2026-07-09Results posted on the registry: Massachusetts General Hospital, Ruxolitinib (NCT03427866)
- 2026-07-07Results posted on the registry: Tu Dan, Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. (NCT04906746)
- 2026-06-30Results posted on the registry: Massachusetts General Hospital, Baricitinib (NCT05189106)
- 2026-06-29Results posted on the registry: University of Texas Southwestern Medical Center, Tofacitinib 10mg + Temozolomide (NCT05326464)
- 2026-06-26Also stopped (terminated): Incyte Corporation, itacitinib (NCT04640025)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision